"Pfizer's Weight-Loss Pill: Another Flop in the Obesity Drug Market"

Pfizer has announced that it will stop developing its twice-daily weight loss pill, danuglipron, after obese patients experienced high rates of adverse side effects in a midstage clinical trial. This comes after Pfizer scrapped a different once-daily pill earlier this year due to elevated liver enzymes. The difficulties in developing effective and safe weight loss treatments are highlighted by the long list of obesity drugs that have been discontinued or pulled from the market due to unintended consequences, such as cancer risks, cardiovascular risks, and serious psychiatric problems. Despite recent breakthrough medications, including Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, the path to treating obesity remains challenging.